Item 5. Market for Registrant’s Common Equity
Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Pyxus’ common stock is currently traded on the OTC Pink Current Marketplace maintained by the OTC Markets Group, Inc., under the symbol "PYYX". On July 1, 2025, the OTC Pink Current Marketplace will be eliminated by the OTC Markets Group, Inc., and PYYX will transfer to the OTCID Basic Market. Over-the-counter market quotations reflect inter-dealer prices, without retail mark-up, mark-down, or commission and may not necessarily represent actual transactions. As of March 31, 2025, the outstanding shares of our common stock were held by one shareholder of record and there were approximately 700 beneficial holders of our common stock.
Issuer Purchase of Equity Securities
The Company did not repurchase any of its equity securities during the three months ended March 31, 2025.
On August 15, 2024, the Board of Directors authorized a program to repurchase up to $10,000,000 plus fees and expenses of our common stock in the open market or through privately negotiated transactions, subject to limitations under the Company's debt agreements (which currently limit the aggregate amount that may be applied to repurchase shares of common stock to $1,000,000). The repurchase by the Company, on August 21, 2024, of shares of its common stock for approximately $1,000,000, inclusive of brokerage fees, was applied to this limit. This program expires on August 15, 2027. If current restrictions under applicable debt agreements are modified to permit further repurchases of common stock by the Company, the number, price, structure and timing of any further share repurchases will be at the Company's sole discretion, and any such future repurchases of our common stock are dependent on market conditions, liquidity needs, and certain restrictions under our debt arrangements, among other factors.
No cash dividends on shares of common stock of Pyxus were paid to shareholders during the fiscal year ended March 31, 2025. The declaration and payment of such dividends is at the discretion of our Board of Directors and subject to our results of operations, financial condition, cash requirements, and other factors, as well as restrictions under applicable law, and our debt agreements.
Item 6. [Reserved]
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.